Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

Rhea-AI Summary

Zynerba Pharmaceuticals (NASDAQ: ZYNE) announced the acceptance of two oral presentations at the virtual AACAP 2020 Annual Meeting occurring from October 12-24, 2020. The presentations will focus on clinical trial responses to Zygel in children and adolescents with Fragile X syndrome and autism spectrum disorder. Dr. Joseph Palumbo expressed gratitude for the opportunity to share significant findings with the scientific community. The oral presentations are scheduled for October 23, 2020, and will discuss the role of methylation status and the efficacy of ZYN002 Cannabidiol transdermal gel.

Positive

• Acceptance of two oral presentations at the AACAP 2020 Annual Meeting highlights clinical trial successes.
• Focus on Zygel demonstrates commitment to addressing rare neuropsychiatric disorders, potentially enhancing investor confidence.

Negative

• None.

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting. The oral presentations will take place during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session. The AACAP annual meeting is being held virtually from October 12^th through October 24^th, 2020. A copy of the slides will be made available on Friday October 23^rd at the time of presentation on the Zynerba corporate website at http://zynerba.com/publications/.

“We are honored to be invited to provide two oral presentations at the virtual AACAP annual meeting to further describe the important responses to Zygel observed in clinical trials in children and adolescents with Fragile X syndrome (FXS) and autism spectrum disorder (ASD), respectively, including data reported by parents and caregivers,” said Joseph Palumbo, MD, FAPA, MACPsych, Chief Medical Officer of Zynerba. “On behalf of participating families and investigators, we look forward to sharing these results with the AACAP scientific community.”

Friday, October 23^rd, 2020 from 2:00 to 4:00 PM EDT

Title: “ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and as a Prognostic Biomarker”
Session: “Research Pipeline: New Findings on Diagnostic and Therapeutics”
Presentation number: 32.8

Title: “Tolerability and Efficacy of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study [BRIGHT (ZYN2-CL-030)]”
Session: “Research Pipeline: New Findings on Diagnostic and Therapeutics”
Presentation number: 32.7

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Zynerba Contact
Will Roberts, VP Investor Relations and Corporate Communications
484.581.7489
robertsw@zynerba.com

Media contact
Molly Devlin
Evoke KYNE
215.928.2199
Molly.Devlin@evokegroup.com

FAQ

What is Zynerba Pharmaceuticals presenting at the AACAP 2020 Annual Meeting?

Zynerba Pharmaceuticals is presenting findings related to Zygel's responses in clinical trials for Fragile X syndrome and autism spectrum disorder.

When are Zynerba's oral presentations scheduled during the AACAP 2020 Annual Meeting?

The oral presentations by Zynerba are scheduled for October 23, 2020, from 2:00 to 4:00 PM EDT.

What is the significance of ZYN002 in Zynerba's research?

ZYN002, a Cannabidiol transdermal gel, is being studied for its tolerability and efficacy in children and adolescents with autism spectrum disorder.

Where can I find more information about Zynerba's presentations?

Further information, including presentation slides, will be available on Zynerba's corporate website following the presentations.

What are the expected topics of Zynerba's presentations at the AACAP meeting?

The presentations will discuss the role of methylation status as a biomarker and the clinical trial data of ZYN002 for Fragile X syndrome and autism.